Pharmacology and Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Methods Mol Biol. 2021;2241:221-242. doi: 10.1007/978-1-0716-1095-4_18.
Mast cells and eosinophils are the key effector cells of allergy [1]. In general, allergic reactions are composed of two phases, namely an early phase and a late phase, and after that resolution occurs. If the allergic reactions fail to resolve after the late phase, allergic inflammation (AI) can evolve into a chronic phase mainly involving mast cells and eosinophils that abundantly coexist in the inflamed tissue in the late and chronic phases and cross-talk in a bidirectional manner. We defined these bidirectional interactions between MCs and Eos, as the "allergic effector unit." This cross talk is mediated by both physical cell-cell contacts through cell surface receptors such as CD48, 2B4, and respective ligands and through released mediators such as various specific granular mediators, arachidonic acid metabolites, cytokines, and chemokines [2, 3]. The allergic effector unit can be studied in vitro in a customized co-culture system using mast cells and eosinophils derived from either mouse or human sources.
肥大细胞和嗜酸性粒细胞是过敏的关键效应细胞[1]。一般来说,过敏反应由两个阶段组成,即早期阶段和晚期阶段,之后是缓解阶段。如果晚期阶段后过敏反应未能缓解,过敏炎症(AI)可以演变为一个慢性阶段,主要涉及肥大细胞和嗜酸性粒细胞,它们在晚期和慢性阶段在炎症组织中大量共存,并以双向方式相互交流。我们将 MCs 和 Eos 之间的这种双向相互作用定义为“过敏效应单元”。这种交流是通过细胞表面受体(如 CD48、2B4 及其各自的配体)的物理细胞-细胞接触以及通过各种特定颗粒介质、花生四烯酸代谢物、细胞因子和趋化因子等释放的介质介导的[2,3]。可以使用源自小鼠或人类的肥大细胞和嗜酸性粒细胞在定制的共培养系统中体外研究过敏效应单元。